SHORT-TERM
STOSSTHERAPY BY METHYLPREDISOLONE (MPSS) IN CHILD PATIENTS WITH SEVERE
ASTHMA (AFFILIATED WITH ANALYSIS OF EIGHTEEN CASES)
Zhang Ruyi
Children’s Hospital,
Chongqing University of Medical Sciences, Chongqing, China
Objective: To
study the outcome of short-term stoss-therapy by mpss in child - patients
with severe asthma.
Methods: All
thirty-two patients who had severe asthma were selected in accordance with
the diagnostic standard of asthma and randomly enrolled into two groups. In
the mpss group (n=18), the dose of mpss was 2-4 mg/kg, q 8h also for three
days while in the control group (n=14), dexamethasone was administered
intravenously with 0.5~0.75 mg /kg, q 8h also for three days. Other
treatments were the same in two groups.
Results: After
three-day treatment, in mpss group, there was a shorter time of duration of
cough, wheezing and stridor than that in control group and the results of P
were <0.01, <0.05 and <0.05, respectively. There were
significantly better results in Pao 2, Paco 2, PH and PEFR (P<0.01). But
in control group, no significant changes were found in Paco 2, PH and PEFR
except Pao 2 with a few changes (P>0.05).
Conclusion:
Asthmatic is a kind of allergic disease with inflammation in airway.
Glucocorticoids are the most effective medication administered to diminish
airway inflammation. The commonly-used glucocorticoids include
dexamethasone, hydrocortisone and mpss. Our data demonstrates that mpss is
better than dexamethasone in anti-inflammation and bronchochilation for child
patients with severe asthma which is the best choice of glucocorticoids to
treat severe asthma.